Navigation Links
Rafarma Pharmaceuticals, Inc. Achieves Full Certification
Date:12/18/2012

Sandy, UT (PRWEB) December 17, 2012

Rafarma Pharmaceuticals, Inc. (the ”Company”) OTC symbol “APKND” announced that its manufacturing and packaging facility in Lipetsk, Russia was fully licensed last November 9th and exhibited by GMP (“Good Manufacturing Practices”) Certificate # 109489 7000-430 (see: http://rafarma.com).

The facility is ISO 9001 and IHC Q 10 compliant. These internationally recognized certifications allow sales and distribution of all permitted products throughout Europe and all nations that are a party to the above standards. The manufacturing facility is currently operating at 30% capacity during its “start-up” phase, and is expected to reach full production during the second quarter of 2013.

With the resignation of Vladimir Bondar as Director and President and Natalia Leonidovna Stupina as Director and CFO due to other commitments, the Company appointed Mr. Sergey Brusnitsin as its new Director and CFO. Mr. Brusnitsin earned his PhD in Economics from the Moscow Institute of Economics and was formerly the director of the Federal Revenue Service of Russia. He has been affiliated with the Company in several capacities throughout its development phase. Mr. Alexander Ageev continues to function as Director, Secretary/Treasurer and Mr. David Anderson will remain as Director and CEO and perform the function of President until the first annual meeting, now scheduled for March 1, 2013.

With expended development costs in excess of $200 million, and expected first year revenue expectations exceeding $100 million, and an excellent product portfolio, the Company is expected to be a leading supplier of pharmaceuticals in the years to come.

The new OTC trading symbol for the Company will be announced by FINRA on January 2, 2013 and be effective January 3, 2013.

Safe Harbor Statement
Matters discussed in this
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
2. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
3. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
4. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
6. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
7. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
8. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
9. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
10. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
11. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 AACC ... to the 2015 AACC Annual Meeting & Clinical ... from July 26–30. The meeting showcased revolutionary advancements ... the ability of healthcare providers to diagnose patients ... effective medical treatment. As of ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... field clinical study of its canine osteoarthritis stem cell product, currently under development ... City, KS) and will be marketed in the US by Aratana. This product, ...
(Date:7/30/2015)... ST. LOUIS, July 30, 2015 ... period in 2014) , Reported sales were $697 ... of 2014.  Sales grew organically by 8%, and changes ... Recent acquisitions increased sales by 1%. , By ... 8% in Applied and 11% in SAFC Commercial. ...
(Date:7/29/2015)... 30, 2015 Sanofi, un ... ses résultats pour le premier semestre 2015. Le ... résultats. Visionner l,interview vidéo et lire ... Au sommaire de l,interview :  ... de croissance - Diabète ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... for 15 minutes, couldn't imagine the influence the Internet, blogging, social ... these tools, everyone can have their 15 minutes - but just ... is about all anyone has time for these days, at least ... reminded of this after coming back from a near three-week holiday ...
... the lead cancer drug candidate of Madison's Quintessence Biosciences ... Food and Drug Aministration for being tested on cancer ... meeting of the American Association for Cancer Research , ... scale and applied in safe doses, the company announced. , ...
... Madison, Wis . - Mithridion, Inc ., a biopharmaceutical ... of Alzheimer's disease, has closed an additional $1.2 million of ... , ,The latest round of funding brings the total equity ... above the company's initial funding target. Mithridion will use the ...
Cached Biology Technology:On the Web, attention spans shrink, the need for value rises 2On the Web, attention spans shrink, the need for value rises 3Quintessence Biosciences advances cancer drug 2Alzheimer's drug developer lands $1.2M in venture funding 2Alzheimer's drug developer lands $1.2M in venture funding 3
(Date:7/30/2015)... 2015 Cellecta, Inc., a U.S.-based provider ... and biomarker discovery, announced the release of its ... all human protein coding genes. CRISPR technology enables ... gene,s function. Cellecta,s new Human Whole Genome CRISPR ... so that researchers can investigate in a single ...
(Date:7/23/2015)... (NASDAQ: AWRE ), a leading supplier of biometrics software ... ended June 30, 2015.  Revenue for the ... 33% compared to $6.8 million in the same quarter last ... $0.3 million, or $0.01 per diluted share, which compared to ... period a year ago.  Lower revenue and ...
(Date:7/21/2015)... OXFORD, Connecticut , July 21, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... the Wocket® smart wallet, announces that it has ... Tokenization System and Method. This ... that not only authorizes an account, but also ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... yourself with a blanket to stave off the shivers? ... help alleviate shivering in patients who have been cooled ... or dangerously high fevers are often cooled to reduce ... aid healing. Unfortunately, cooling induces a natural and familiar ...
... Tiny flying machines can be used for everything ... simply making smaller versions of planes and helicopters ... Carolina State University are mimicking nature,s small flyers ... maneuverability and performance. Small flyers, or micro-aerial ...
... from the British Antarctic Survey have collected individuals from a ... subjected them to increasing levels of water temperature to learn ... that they are likely to experience in the future. The ... really close to their upper temperature range, and that further ...
Cached Biology News:Robo-bats with metal muscles may be next generation of remote control flyers 2
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
MAb to Desmoplakin I & II Desmoplakin I & II...
BD Biocoat Matrigel Matrix Thin Layer 35 mm Culture Dishes...
... of ICE-family proteases/caspases initiates apoptosis in mammalian ... Detection Kit provides a simple and convenient ... flow cytometry in intact cells. The ... aspartate residues linked to rhodamine 110 (D2R), ...
Biology Products: